COMMUNIQUÉS West-GlobeNewswire

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
26/11/2025
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to [...]
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
26/11/2025
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah [...]
CG Oncology Announces New Board Member and Board Transition
26/11/2025
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical [...]
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
26/11/2025
Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the [...]
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
26/11/2025
Kuros Biosciences to present at the Piper Sandler 37 th Annual Healthcare Conference Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic [...]
Valneva annonce des résultats finaux positifs de Phase 2 pour son candidat vaccin contre la maladie de Lyme
26/11/2025
Les taux d'anticorps sont restés supérieurs à leur niveau initial pour les six sérotypes et dans toutes les tranches d’âge six mois après la dernière injection des trois doses de rappel Aucun problème de sécurité n’a [...]
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
26/11/2025
Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose No safety concerns observed in any age group by an independent Data Monitoring Committee ( [...]
Galapagos Receives Transparency Notifications from Bank of America
26/11/2025
Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation [...]
La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS
26/11/2025
La Thérapie Genio® de Nyxoah Bénéficie d'une Augmentation Significative du Remboursement Medicare en 2026 en Vertu de la Règle Finale du CMS L'attribution à l’APC "nouvelle technologie" 1580 donne un élan significatif [...]
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
26/11/2025
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening [...]
Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate
26/11/2025
The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi platform into [...]
Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®
26/11/2025
Suite aux avis favorables rendus par le Comité des médicaments à usage humain (CMUH ) , la Commission européenne a accordé des autorisations de mise en marché visant les biosimilaires PONLIMSI et DEGEVMA de Teva, [...]
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
25/11/2025
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
25/11/2025
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
25/11/2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
25/11/2025
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patients IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG [...]
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
25/11/2025
HOUSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
LENZ Therapeutics to Present at Upcoming Investor Conferences
25/11/2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1. [...]
Surrozen to Present at Upcoming Healthcare Investor Conferences
25/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]

Pages